Overall, we investigated the heterogeneity of TME from a single-cell perspective and demonstrated that SEMA3C serve as an effective biomarker for predicting lymph node metastasis and prognosis in PSCC. The gene discussed is SEMA3C; the disease is metastatic malignant neoplasm in the lymph nodes.